Emerging roles of fibroblast growth factor 21 in critical disease

Fang Yan; Li Yuan; Fan Yang; Guicheng Wu; Xiaobo Jiang

doi:10.3389/fcvm.2022.1053997

Emerging roles of fibroblast growth factor 21 in critical disease

Front Cardiovasc Med. 2022 Nov 10:9:1053997. doi: 10.3389/fcvm.2022.1053997. eCollection 2022.

Authors

Fang Yan^{1

2}, Li Yuan³, Fan Yang⁴, Guicheng Wu⁵, Xiaobo Jiang⁶

Affiliations

¹ Department of Geriatrics, Chengdu Fifth People's Hospital, Geriatric Diseases Institute of Chengdu, Chengdu, China.
² Center for Medicine Research and Translation, Chengdu Fifth People's Hospital, Chengdu, China.
³ Department of Clinical Laboratory Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
⁴ Department of Endocrinology, Chengdu Fifth People's Hospital, Chengdu, China.
⁵ Department of Hepatology, School of Medicine, Chongqing Municipality Clinical Research Center for Endocrinology and Metabolic Diseases, Chongqing University Three Goreges Hosipital, Chongqing University, Chongqing, China.
⁶ Department of Cardiology, Chengdu Fifth People's Hospital, Chengdu, China.

Abstract

In spite of the great progress in the management of critical diseases in recent years, its associated prevalence and mortality of multiple organ failure still remain high. As an endocrine hormone, fibroblast growth factor 21 (FGF21) functions to maintain homeostasis in the whole body. Recent studies have proved that FGF21 has promising potential effects in critical diseases. FGF21 has also been found to have a close relationship with the progression of critical diseases and has a great predictive function for organ failure. The level of FGF21 was elevated in both mouse models and human patients with sepsis or other critical illnesses. Moreover, it is a promising biomarker and has certain therapeutic roles in some critical diseases. We focus on the emerging roles of FGF21 and its potential effects in critical diseases including acute lung injury/acute respiratory distress syndrome (ALI/ARDS), acute myocardial injury (AMI), acute kidney injury (AKI), sepsis, and liver failure in this review. FGF21 has high application value and is worth further studying. Focusing on FGF21 may provide a new perspective for the management of the critical diseases.

Keywords: acute kidney injury; acute lung injury; acute myocardial injury; acute respiratory distress syndrome; fibroblast growth factor 21; sepsis.

Publication types

Review